Next Article in Journal
Psychedelics for Psychological and Existential Distress in Palliative and Cancer Care
Previous Article in Journal
Gaps and Delays in Survivorship Care in the Return-to-Work Pathway for Survivors of Breast Cancer—A Qualitative Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 26
Issue 3
10.3747/co.26.4381
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Case Report

Fatal Myocarditis and Rhabdomyositis in a Patient with Stage Iv Melanoma Treated with Combined Ipilimumab and Nivolumab

by
S. D. Saibil
1,
L. Bonilla
1,
H. Majeed
1,
V. Sotov
1,
D. Hogg
1,
M. A. Chappell
1,
M. Cybulsky
2,3 and
M. O. Butler
1,3,*
1
Department of Medical Oncology and Haematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
2
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada
3
University Health Network, Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2019, 26(3), 418-421; https://doi.org/10.3747/co.26.4381
Submission received: 6 March 2019 / Revised: 8 April 2019 / Accepted: 12 May 2019 / Published: 1 June 2019

Abstract

Combination immune checkpoint blockade with concurrent administration of the anti-CTLA4 antibody ipilimumab and the anti–PD-1 antibody nivolumab has demonstrated impressive responses in patients with advanced melanoma and other diseases. That combination has also been associated with increased toxicity, including rare immune-related adverse events. Here we describe a case of fatal steroid-refractory myocarditis and panmyositis associated with the use of this combination in a patient with metastatic melanoma. Correlative studies indicated increased levels of serum interleukin 6 in this patient at the onset of toxicity, suggesting a possible role for anti–interleukin 6 receptor antibodies in the treatment of subsequent cases of this rare, but fatal, toxicity.
Keywords: melanoma; checkpoint blockade; myocarditis melanoma; checkpoint blockade; myocarditis

Share and Cite

MDPI and ACS Style

Saibil, S.D.; Bonilla, L.; Majeed, H.; Sotov, V.; Hogg, D.; Chappell, M.A.; Cybulsky, M.; Butler, M.O. Fatal Myocarditis and Rhabdomyositis in a Patient with Stage Iv Melanoma Treated with Combined Ipilimumab and Nivolumab. Curr. Oncol. 2019, 26, 418-421. https://doi.org/10.3747/co.26.4381

AMA Style

Saibil SD, Bonilla L, Majeed H, Sotov V, Hogg D, Chappell MA, Cybulsky M, Butler MO. Fatal Myocarditis and Rhabdomyositis in a Patient with Stage Iv Melanoma Treated with Combined Ipilimumab and Nivolumab. Current Oncology. 2019; 26(3):418-421. https://doi.org/10.3747/co.26.4381

Chicago/Turabian Style

Saibil, S. D., L. Bonilla, H. Majeed, V. Sotov, D. Hogg, M. A. Chappell, M. Cybulsky, and M. O. Butler. 2019. "Fatal Myocarditis and Rhabdomyositis in a Patient with Stage Iv Melanoma Treated with Combined Ipilimumab and Nivolumab" Current Oncology 26, no. 3: 418-421. https://doi.org/10.3747/co.26.4381

APA Style

Saibil, S. D., Bonilla, L., Majeed, H., Sotov, V., Hogg, D., Chappell, M. A., Cybulsky, M., & Butler, M. O. (2019). Fatal Myocarditis and Rhabdomyositis in a Patient with Stage Iv Melanoma Treated with Combined Ipilimumab and Nivolumab. Current Oncology, 26(3), 418-421. https://doi.org/10.3747/co.26.4381

Article Metrics

Back to TopTop